{"id":25799,"date":"2025-05-28T14:46:50","date_gmt":"2025-05-28T13:46:50","guid":{"rendered":"https:\/\/www.businessmole.com\/?p=25799"},"modified":"2025-05-28T14:46:50","modified_gmt":"2025-05-28T13:46:50","slug":"bombshell-pfizergate-ruling-lays-bare-urgency-of-eu-transparency-overhaul","status":"publish","type":"post","link":"https:\/\/www.businessmole.com\/bombshell-pfizergate-ruling-lays-bare-urgency-of-eu-transparency-overhaul\/","title":{"rendered":"Bombshell \u2018Pfizergate\u2019 ruling lays bare urgency of EU transparency overhaul"},"content":{"rendered":"<div>\n<p><span lang=\"EN-US\">More than two years after the\u00a0<i>New York Times<\/i>\u00a0first broke the scandal, the \u2018Pfizergate\u2019 case has\u00a0<a title=\"This external link opens in a new window\" href=\"https:\/\/verfassungsblog.de\/pfizergate-rule-of-law-eu-commission\/\" target=\"_blank\" rel=\"noopener\">reached<\/a>\u00a0an explosive climax.<\/span><\/p>\n<p><span lang=\"EN-US\">On 14 May, the European Court of Justice (ECJ) ruled against the European Commission on all counts. Annulling the latter\u2019s refusal to release text messages between Commission President Ursula von der Leyen and Pfizer CEO Albert Bourla during Covid-19 vaccine negotiations, the court\u2019s decision concludes that the Commission failed to provide \u201ca plausible explanation\u201d for its actions that \u201cbreached the principle of good administration.\u201d<\/span><\/p>\n<p><span lang=\"EN-US\">Observers consider the ruling both a legal milestone and political bombshell for von der Leyen, whose reputation and authority has been directly challenged just six months into her new mandate. Meanwhile, transparency advocates have framed the verdict as a major victory and stark reminder of the EU executive\u2019s selective observance of governance laws.<\/span><\/p>\n<p><span lang=\"EN-US\">As Transparency International\u2019s Shari Hinds has rightly asserted, \u201cthis ruling is\u2026about reinstating the institutional accountability the European Commission has been sorely lacking\u201d \u2013 a transparency gap the tobacco industry has particularly consistently exploited under von der Leyen\u2019s watch to weaken public health policies. With EU tobacco control reform on the horizon, this major vulnerability must no longer go unchallenged.<\/span><\/p>\n<p><b><span lang=\"EN-US\">Deeper dive into Pfizergate<\/span><\/b><\/p>\n<p><span lang=\"EN-US\">Already under fire for its increasing centralisation of power and green policy backtracking, the &#8216;Pfizergate&#8217; decision darkens the cloud hanging over von der Leyen&#8217;s second term. The ECJ ruling is particularly damaging as the EU chief not only personally approved the multi-billion vaccine deal \u2013 the EU\u2019s largest-ever contract \u2013 but leads the very institution tasked with upholding the bloc\u2019s transparency laws.<\/span><\/p>\n<p><span lang=\"EN-US\">At the heart of the Pfizergate case is the question of whether text messages should be considered official documents subject to EU governance rules. While transparency advocates and legal experts insist they should be treated no differently from emails or other formal communications, the Commission has maintained the opposite view. After months of Commission stonewalling,\u00a0<i>The New York Times<\/i>\u00a0and its former Brussels bureau chief escalated the matter to the ECJ in early 2023, demanding access to the von der Leyen-Bourla messages.<\/span><\/p>\n<p><span lang=\"EN-US\">In parallel, then-European Ombudsman Emily O\u2019Reilly ruled in 2022 that the EU executive\u2019s failure to retrieve the Pfizergate messages amounted to maladministration, adding that transparency had deteriorated under von der Leyen. Indeed, the Commission avoided even acknowledging the messages\u2019 existence for years, only doing so at a court hearing last November. Moreover, ECJ judges repeatedly pressed the Commission on its method for determining whether the texts warranted qualification as official documents \u2013 questions the EU executive was unable, or unwilling, to answer convincingly.<\/span><\/p>\n<p><span lang=\"EN-US\">Following the court\u2019s ruling, the Commission issued a brief statement saying it would review the decision and issue a new explanation addressing\u00a0<i>The New York Times\u2019<\/i>s\u00a0 original request \u2013 yet the saga is far from over. In March, the European Public Prosecutor\u2019s Office (EPPO) confirmed that it is investigating the Commission\u2019s handling of vaccine procurement, raising the stakes further in a case undermining the EU executive\u2019s legitimacy.<\/span><\/p>\n<p><b><span lang=\"EN-US\">Big Tobacco exploiting Commission\u2019s culture of secrecy<\/span><\/b><\/p>\n<p><span lang=\"EN-US\">Among the Green MEPs who brought a separate case to the EU\u2019s General Court over the Commission\u2019s redaction of vaccine contracts, Tilly Metz offered a pointed reminder after the Pfizergate ruling. \u201cIf you want the public to\u2026trust the politicians,\u201d as well as their contacts with industry, \u201cyou have to put the focus on transparency,\u201d Metz affirms. As the Vice President of the SANT Committee, Metz recently emphasised the need for bolder action on another critical health policy issue long compromised by the Commission&#8217;s transparency lapses: tobacco.<\/span><\/p>\n<p><span lang=\"EN-US\">Given tobacco\u2019s place among the leading causes of death in Europe, Metz\u2019s contribution to the 9 May EP plenary debate urged Brussels to &#8220;stop beating around the bush,&#8221; with the recent years of inaction stemming from the Commission&#8217;s weakness in the face of aggressive Big Tobacco lobbying. Exemplifying this dynamic, the Commission\u2019s unexplained decision to block the Tobacco Taxation Directive revision in December 2022 \u2013 prominently spotlighted by the Smoke-Free Partnership\u2019s Lilia Olefir \u2013 raises a pressing question. As with Pfizergate, are there undisclosed text messages with tobacco companies behind this and other industry wins in recent years?<\/span><\/p>\n<p><span lang=\"EN-US\">Following the 2014 Tobacco Products Directive (TPD) review \u2013 during which tobacco lobbyists successfully stripped out provisions for an independent, WHO FCTC-compliant tobacco traceability system \u2013 the Commission allowed the tobacco industry and its partners\u2019 influence to seep into the EU\u2019s policy framework with little resistance or oversight. Since 2019, tobacco industry allies Dentsu Tracking, Inexto and Atos have operated the EU\u2019s tobacco traceability system, with their close links to the Philip Morris International-developed Codentify system directly violating WHO rules.\u00a0<\/span><\/p>\n<p><span lang=\"EN-US\">In countries such as Lithuania, Inexto and Atos have falsely promoted Codentify as a WHO-compliant traceability technology. What\u2019s more, Dentsu Tracking, owner of Codentify co-developer Blue Infinity, has sparked significant controversy for winning its Commission contract without an open public tender and neglecting to register in the EU Transparency Register during its years-long, Big Tobacco-backed lobbying of the EU executive. Given the EU\u2019s direct funding of Dentsu \u2013 contrary to then-EU Health Commissioner Kyriakides\u2019s written claim that its Japanese parent company had not received EU money \u2013 this transgression raises serious maladministration concerns which warrant the EPPO\u2019s attention.<\/span><\/p>\n<p><span lang=\"EN-US\">In 2023, Former Ombudsman Emily O\u2019Reilly notably issued a maladministration ruling on the Commission\u2019s dealings with tobacco lobbyists, while an EP group led by former MEP Anne-Sophie Pelletier and supported by civil society experts produced a White Paper early last year exposing the costs of this revolving-door relationship. With illicit trade rising and billions in tax revenue lost annually across the EU, Pelletier\u2019s recently-launched SANITAS initiative aims to secure real safeguards in the upcoming TPD review and avoid repeating the mistakes of the past.<\/span><\/p>\n<p><b><span lang=\"EN-US\">Building back up from the ruins<\/span><\/b><\/p>\n<p><span lang=\"EN-US\">In the current European Parliament, Pelletier and her civil society allies will find committed partners \u2013 especially within the ranks of the SANT Committee. For example, Lithuanian MEPs Aurelijus Veryga and Vytenis Andriukaitis bring deep expertise and longstanding dedication to tobacco control, with Veryga having founded Lithuania\u2019s National Tobacco Control Coalition and Andriukaitis having warned as early as 2016 against the tobacco industry\u2019s role in tackling the EU\u2019s illicit tobacco trade.<\/span><\/p>\n<p><span lang=\"EN-US\">A continuation of her ambitious work on tobacco while serving as an MEP, Pelletier\u2019s SANITAS paves the way for meaningful tobacco control regulation driven primarily by the public\u2019s interest. Moving forward, the SANT Committee has an opportunity to correct the course of EU tobacco policy and leave a legacy of transparency action, building on the momentum of ECJ&#8217;s landmark stand against the Commission&#8217;s culture of secrecy and opaque dealings with noxious industries.<\/p>\n<p>The\u00a0<i>Pfizergate<\/i>\u00a0ruling has laid bare a deeper crisis at the EU\u2019s core: a failure of accountability that erodes trust and opens the door to powerful lobbies that undermine public health. As the EU prepares to reform its tobacco control framework and advance other vital health files, it must treat this judgment as a turning point. Transparency must no longer be viewed in Brussels as an optional, selectively-applied exercise, but rather as the first line of defence against corporate capture and the only way to rebuild credibility where it\u2019s been lost.<\/span><\/p>\n<\/div>\n<div><\/div>\n","protected":false},"excerpt":{"rendered":"More than two years after the\u00a0New York Times\u00a0first broke the scandal, the \u2018Pfizergate\u2019 case has\u00a0reached\u00a0an explosive climax. On&hellip;\n","protected":false},"author":10,"featured_media":25800,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","csco_singular_sidebar":"","csco_page_header_type":"","csco_appearance_masonry":"","csco_page_load_nextpost":"","csco_post_video_location":[],"csco_post_video_location_hash":"","csco_post_video_url":"","csco_post_video_bg_start_time":0,"csco_post_video_bg_end_time":0},"categories":[699],"tags":[],"_links":{"self":[{"href":"https:\/\/www.businessmole.com\/wp-json\/wp\/v2\/posts\/25799"}],"collection":[{"href":"https:\/\/www.businessmole.com\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.businessmole.com\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.businessmole.com\/wp-json\/wp\/v2\/users\/10"}],"replies":[{"embeddable":true,"href":"https:\/\/www.businessmole.com\/wp-json\/wp\/v2\/comments?post=25799"}],"version-history":[{"count":1,"href":"https:\/\/www.businessmole.com\/wp-json\/wp\/v2\/posts\/25799\/revisions"}],"predecessor-version":[{"id":25801,"href":"https:\/\/www.businessmole.com\/wp-json\/wp\/v2\/posts\/25799\/revisions\/25801"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.businessmole.com\/wp-json\/wp\/v2\/media\/25800"}],"wp:attachment":[{"href":"https:\/\/www.businessmole.com\/wp-json\/wp\/v2\/media?parent=25799"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.businessmole.com\/wp-json\/wp\/v2\/categories?post=25799"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.businessmole.com\/wp-json\/wp\/v2\/tags?post=25799"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}